Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details two specific transactions affecting shareholdings:
- Employee Share Option Plan Transfer: On July 15, 2005, Abacus (GSK) Trustees Limited transferred 772 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan Adjustment: On July 14, 2005, the GlaxoSmithKline US Retirement Savings Plan saw a reduction in Ordinary Share ADRs from 18,343,942 to 18,322,085 due to a fund movement. The average price for this movement was $48.22.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on compliance with Disclosure rule 3.1.4R(1)(b) regarding director and employee trust interests.
Investor Verification Points
- Verify the impact of the 21,857 ADR reduction in the US Retirement Savings Plan on overall insider ownership percentages.
- Confirm the specific directors (Dr J-P Garnier, Dr T Yamada, Mr J S Heslop) with potential interests in the GSK Trust and US Retirement Plan.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting or exercise conditions for the 772 shares transferred.